At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
L-Threonic Acid Magnesium Salt (L-TAMS)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
L-Threonic Acid Magnesium Salt (L-TAMS) in ADHD: An Open-label Pilot Study of Cognitive and Functional Effects
In Brief
A Phase 2 clinical trial evaluating L-Threonic Acid Magnesium Salt (L-TAMS) for Attention Deficit/Hyperactivity Disorder and ADHD. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This study is a 12-week, open-label pilot study to test the effects of MMFS-201-301 on cognition and function in adults with ADHD. Subjects may enter the trial on a stable dose of medication for ADHD, and MMFS-201-301 will be given. Subjects who do not enter on a stable dose of ADHD medication will receive MMFS-201-301 alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit/Hyperactivity Disorder, ADHD
CountriesUnited States
CollaboratorsNeurocentria, Inc.
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartMar 2016
Primary CompletionOct 2017
TodayJul 2026
First PostedSep 24, 2015
Enrollment StartMar 1, 2016
Primary CompletionOct 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 10.8 years ago
Interventions
L-Threonic Acid Magnesium Salt (L-TAMS)drug